; (ii) the active pharmaceutical ingredients of such drugs; or (iii) active pharmaceutical ingredients on such list; (B) the amount of such finished dosage forms and active pharmaceutical ingredients produced at each such establishment; (C) to the extent available— (i) the location of establishments involved in the production of the key starting materials and excipients used to produce the finished dosage forms and active pharmaceutical ingredients referred to in subparagraph (A); and (ii) the amount of such materials and excipients produced at each such establishment; and (D) any regulatory actions with respect to the establishments referred to in subparagraph (A) or (C), including with respect to— (i) labeling requirements; (ii) registration and listing information required to be submitted under section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 ); (iii) inspections and related regulatory activities conducted under section 704 of such Act ( 21 U.S.C. 374 ); (iv) the seizure of such a drug or active pharmaceutical ingredient pursuant to section 304 of such Act ( 21 U.S.C. 334 ); (v) any recalls of a drug or active pharmaceutical ingredient on the list of essential medicines under section 2(a), or a drug containing an active pharmaceutical ingredient on such list; (vi) inclusion of such a drug or active pharmaceutical ingredient on the drug shortage list under section 506E of such Act ( 21 U.S.C. 356e ); or (vii) prior reports of a discontinuance or interruption in the production of such a drug or active pharmaceutical ingredient under 506C of such Act ( 21 U.S.C. 356c ). (b) Report Not later than 18 months after the date of enactment of this Act, and annually thereafter, the Secretary of Health and Human Services, in consultation with the heads of agencies with which such Secretary coordinates under subsection (a), shall submit a report to Congress on— (1) progress on implementing subsection (a), including any timelines for full implementation